Postischemic treatment (2–4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat
ZG Zhang, M Chopp, WX Tang, N Jiang, RL Zhang - Brain research, 1995 - Elsevier
ZG Zhang, M Chopp, WX Tang, N Jiang, RL Zhang
Brain research, 1995•ElsevierWe investigated the effects of F (ab′) 2 fragments of anti-CD11b and anti-CD18
monoclonal antibodies on ischemic cell damage in the rat when administered upon
reperfusion and at 2 h of reperfusion after transient (2 h) middle cerebral artery (MCA)
occlusion. 2 h of MCA occlusion was induced by intraluminal insertion of a monofilament.
The following groups of animals were investigated. Anti-CD11b groups (n= 15): an intact anti-
CD11b antibody (1B6c) and an anti-CD11b F (ab′) 2 fragment of 1B6c were infused upon …
monoclonal antibodies on ischemic cell damage in the rat when administered upon
reperfusion and at 2 h of reperfusion after transient (2 h) middle cerebral artery (MCA)
occlusion. 2 h of MCA occlusion was induced by intraluminal insertion of a monofilament.
The following groups of animals were investigated. Anti-CD11b groups (n= 15): an intact anti-
CD11b antibody (1B6c) and an anti-CD11b F (ab′) 2 fragment of 1B6c were infused upon …
We investigated the effects of F(ab′)2 fragments of anti-CD11b and anti-CD18 monoclonal antibodies on ischemic cell damage in the rat when administered upon reperfusion and at 2 h of reperfusion after transient (2 h) middle cerebral artery (MCA) occlusion. 2 h of MCA occlusion was induced by intraluminal insertion of a monofilament. The following groups of animals were investigated. Anti-CD11b groups (n = 15): an intact anti-CD11b antibody (1B6c) and an anti-CD11b F(ab′)2 fragment of 1B6c were infused upon reperfusion (4 mg/kg i.v.). Anti-CD18 group (n = 8): an anti-CD18 F(ab′)2 fragment of CL26 was infused upon reperfusion (2 mg/kg i.v.), and at 22 h of reperfusion (1 mg/kg i.v.). Anti-CD11b delayed group (n = 9): an anti-CD11b F(ab′)2 fragment of 1B6c was infused at 2 h of reperfusion (4 mg/kg i.v.), and at 22 h after reperfusion (2 mg/kg i.v.). Control groups (n = 18): an isotype-matched control antibody (mouse IgG1) was administered: (a) upon reperfusion (n = 13), and (b) at 2 h and 22 h of reperfusion (n = 5). Rats were sacrificed at 7 days of reperfusion. In a separate population of rats subjected to 2 h of MCA occlusion (n = 9), brain myeloperoxidase (MPO) activity was measured at 46 h of reperfusion. The vehicle groups had infarct volumes of 35.21 ± 2.82% to 41.39 ± 2.73% of the contralateral hemisphere, respectively. Infarct volume was significantly reduced after treatment with: the intact anti-CD11b antibody upon reperfusion (19.0 ± 6.6%) (P < 0.05), the fragments of mAbs of anti-CD11b administered upon reperfusion (19.7 ± 2.7%) (P < 0.05), and at 2 h of reperfusion (22.2 ± 4.8%) (P < 0.05), and anti-CD18 administered upon reperfusion (20.4 ± 4.8%) (P < 0.05). Anti-CD11b treatment significantly (P < 0.05) inhibited the increase of MPO activity in the ischemic hemisphere. Our data demonstrate that anti-CD11b and anti-CD18 mAb fragments significantly reduce infarct volume and inhibit the increase of MPO activity in the ischemic lesion; administration of anti-CD11b mAb fragment even at 2 h of reperfusion significantly reduces infarct volume. These data support importance of the β 2 integrin CD11b/CD18 in ischemia/reperfusion injury and indicate that the therapeutic window for intervention to reduce ischemic cell damage in this model is at least 4 h from the onset of MCA occlusion.
Elsevier